1. HOME
2. Research Insight
3. Biomarkers Companies - F. Hoffmann-La Roche Ltd (Switzerland) and Merck KGaA (Germany) are the Leading Players

The biomarkers market is expected to reach USD 93.8 billion in 2029 from USD 57.7 billion in 2024, at a CAGR of 10.2% during the forecast period. The major factors driving the growth of this market include the growing importance of companion diagnostics, the increase in the global prevalence of cancer, and the growing importance of biomarkers for rare conditions.

The biomarkers market is highly competitive.

Major Biomarkers Market Companies include

• F. Hoffmann-La Roche Ltd (Switzerland),
• Merck KGaA (Germany),
• Thermo Fisher Scientific Inc. (US),
• Abbott (US),
• QIAGEN (Germany) and many more....

The market players have adopted various strategies such as new product launches, acquisitions, agreements, collaborations, partnerships, and geographical expansions to strengthen their position in the global biomarkers market.

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche Ltd (Switzerland):

F. Hoffmann-La Roche Ltd is a research-based global healthcare company with expertise in diagnostics and pharmaceuticals. The company develops and manufactures innovative medicines, diagnostic instruments, and tests. The company mainly operates in the US, the UK, Switzerland, Oceania, Japan, Germany, Spain, France, Austria, Brazil, and Belgium, among other countries. Roche offers a wide range of products and services in the biomarkers market. This includes a comprehensive portfolio of diagnostic tests and technologies for detecting and measuring biomarkers associated with various diseases such as cancer, infectious diseases, cardiovascular disorders, and more. Their assays and tests aid in the early detection, monitoring, and treatment selection of patients. Additionally, the company continues to develop and manufacture innovative products. For instance, in February 2023, F. Hoffmann-La Roche Ltd launched two new antibodies to understand a patient's brain tumor mutation status in the IDH1 and ATRX genes that help in more informed clinical decisions and may improve patient outcomes.

Merck KGaA (Germany):

Merck KGaA is a healthcare & life sciences company that develops, manufactures, and markets pharmaceutical and biopharmaceutical products, specialty chemicals, high-tech materials, and life science research and diagnostic tools. The company offers various biomarkers products, including reagents, kits, assays, and software, catering to various research, bioprocessing, and clinical applications. The company has a strong international presence, with a wide distribution network and established relationships with research institutions, biotech, and pharmaceutical companies worldwide. Additionally, the company has strategically expanded its global footprint by developing collaborations and partnerships. For instance, in January 2024, Quibim and Merck KGaA partnered to develop diagnostic tools to build the next generation of precision medicine technology targeting a wide range of cancers.

Thermo Fisher Scientific Inc. (US):

Thermo Fisher Scientific is one of the leading players in the life science industry. The company develops, manufactures, sells, and distributes analytical instruments, equipment, reagents & consumables, software, and services. The company is known for its premier brands, such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. With a global presence and a reputation for high-quality products and innovative technologies, Thermo Fisher Scientific is a trusted partner for laboratories, research institutions, and pharmaceutical companies involved in biomarker research. Their commitment to advancing scientific research and improving patient outcomes makes them a key player in the biomarkers market. The company operates in over 180 countries across North America, Europe, Asia, the Middle East, Africa, and Latin America. Further, the company continues to invest in research and development to offer innovative and a broad range of products. For instance, in 2023, the company invested USD 1.34 billion in research and development.

Major Biomarkers Market manufacturers include

• Roche Diagnostics (Switzerland),
• Siemens Healthineers (Germany),
• Bio-Rad Laboratories (United States) and many more....

Researching global manufacturers in the biomarkers industry would involve examining various aspects such as the types of biomarkers they specialize in, their geographic reach, key products, technological advancements, partnerships, and market share.

Roche Diagnostics (Switzerland):

• Specialization: Offers a wide range of biomarker assays for oncology, infectious diseases, cardiovascular diseases, and neurology.
• Geographic Reach: Operates globally with a strong presence in Europe, North America, Asia-Pacific, and other regions.
• Key Products: cobas® series for molecular diagnostics, Elecsys® immunoassays for protein biomarkers.
• Technological Advancements: Invests in next-generation sequencing (NGS) and digital PCR technologies for biomarker discovery.
• Partnerships: Collaborates with academic institutions and biotech companies for biomarker research and development.
• Market Share: Holds a significant share in the global biomarkers market, particularly in oncology diagnostics.
• Regulatory Compliance: Adheres to FDA and CE regulations for biomarker assay validation and commercialization.

Siemens Healthineers (Germany):

• Specialization: Offers a broad portfolio of biomarker assays for various disease areas including oncology, cardiology, and infectious diseases.
• Geographic Reach: Operates globally with a strong presence in Europe, North America, Asia-Pacific, and other regions.
• Key Products: ADVIA Centaur® immunoassay system, Atellica® Solution for laboratory diagnostics, and Aptio® Automation for workflow efficiency.
• Technological Advancements: Invests in automation, digitalization, and artificial intelligence for biomarker analysis and interpretation.
• Partnerships: Collaborates with academic institutions and healthcare providers for biomarker research and clinical validation.
• Market Share: Holds a significant share in the global in vitro diagnostics market, particularly in immunoassay and clinical chemistry.

Bio-Rad Laboratories (United States):

• Specialization: Offers a diverse range of biomarker solutions including immunoassays, molecular diagnostics, and digital PCR.
• Geographic Reach: Operates globally with a strong presence in North America, Europe, Asia-Pacific, Latin America, and other regions.
• Key Products: Bio-Plex multiplex immunoassay system, QX200 Droplet Digital PCR System, and SARS-CoV-2 diagnostic assays.
• Technological Advancements: Invests in multiplexed assays, digital PCR, and data analysis software for biomarker discovery and validation.
• Partnerships: Collaborates with academic institutions and pharmaceutical companies for biomarker research and development.
• Market Share: Holds a significant share in the global life sciences and diagnostics markets, particularly in protein analysis and PCR.

These companies represent some of the leading global manufacturers in the biomarkers industry, contributing significantly to advancements in personalized medicine, disease diagnostics, and therapeutic development worldwide.

Related Reports:

Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) & Region - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]